Newman Fellows are appointed on an ongoing basis, as funding becomes available. Current Newman Fellows include:
Susan will use her Fellowship to participate in a collaborative effort to standardise method scoring and reporting of tumour budding that will enable adoption into routine clinical practice and seek to improve treatment decisions in colorectal cancer. Susan is mentored by Professor Kieran Sheahan.
Dina will use her Fellowship to assess the frequency of anxiety and depression and quality of life of patients with cervical dystonia, a movement disorder which causes excessive, spasmodic contractions of the neck muscles to determine. As the cause of cervical dystonia is completely unknown Dina will examine initial evidence from other researchers of disordered processing of the emotional content of social stimuli in these individuals which will improve the understanding of the causes of these symptoms in cervical dystonia and their treatments. Dina will also study the factors contributing to the development of musician’s Dystonia, an uncommon movement disorder which can severely disable a professional musician’s career. Dina is mentored by Professor Michael Hutchinson.
Secondary Progressive Multiple Sclerosis (SPMS) is a phase of Multiple Sclerosis developed by about 65% of MS sufferers approximately 15 years after diagnosis. It is characterised by a gradual progression of the condition and an incomplete recovery from relapses. Dr Yap’s Fellowship will study SPMS through a pilot study of the effects of high-dose simvastatin, high-dose Vitamin D, fingolimod and placebo on cerebrospinal neurofilament levels in SPMS patients. Dr Yap has identified a significant area of unmet need in therapy for patients with SPMS to reduce the rate of progressive disability and cognitive loss. Dr Yap is supervised by Dr Glen Doherty and based in the St Vincent’s University Hospital Education & Research Centre.
Dr Yap’s Fellowship is supported by Novartis. Novartis provides healthcare solutions that address the evolving needs of patients and societies.
Dr Stephen Duff is using his fellowship to investigate novel biomarkers of Acute Kidney Injury. He is focusing on the development of new markers for doctors to diagnose kidney injury and as early as possible in critically ill patients and in patients after having major surgery. Currently these conditions are very hard to treat as they are detected by doctors often after the main injury has occurred. These new markers will allow the treatment of these illnesses earlier and will help develop new treatments. Using a well-established collection of samples from patients with acute kidney injury, Stephen will measure the presence of proteins that will inform about the health of the kidney. New ways that tell us earlier and more reliably, if a patient’s kidneys are failing will be identified. This will mean that doctors will have better read outs and can more accurately predict how patients will do. This programme builds on existing strengths in Acute kidney injury, in biobanking and in biomarker discovery, analysis and validation.
Dr Duff is mentored by Professor Patrick Murray, Professor of Clinical Pharmacology at UCD and is based in the UCD School of Medicine and the UCD Clinical Research Centre. This Fellowship is supported by Abbott Diagnostics, the global healthcare company that conducts innovative research and manufactures products for human health through every life stage.
About 2,200 cases of lung cancer are diagnosed in Ireland each year and it ranks as the fourth most common cancer. Unfortunately, more Irish men and women die from lung cancer than any other type of cancer. Lung cancer cases can be divided into two types; small cell lung cancer and non-small cell lung cancer (NSCLC). Most lung cancers are of the non-small cell type. NSCLC’s can be further divided into Adenocarcinoma, Squamous cell carcinoma and Large cell carcinoma. There are many mutations that happen in lung cells that are currently being examined by scientific researchers. These mutations can contribute to the development of lung cancer. Two proteins can become involved in cancerous mutations, Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (Alk). Dr Crisetti aims to determine the frequency of EGFR and Alk mutations in an Irish population, and correlate this with clinical outcome, cancer stage and smoking status. This translational medicine project aims to use exosome biology to identify potential biomarkers to allow the potential development of targeted therapies defined by the patient’s tumour profile. The ultimate aim is to improve patient care. Dr Crisetti is mentored by Professor Michael Keane and based at the UCD Conway Institute of Bimolecular and Biomedical Research.
About 2,200 cases of lung cancer are diagnosed in Ireland each year and it ranks as the fourth most common cancer. Unfortunately, more Irish men and women die from lung cancer than any other type of cancer. Lung cancer cases can be divided into two types; small cell lung cancer and non-small cell lung cancer (NSCLC). Most lung cancers are of the non-small cell type. NSCLC’s can be further divided into Adenocarcinoma, Squamous cell carcinoma and Large cell carcinoma. There are many mutations that happen in lung cells that are currently being examined by scientific researchers. These mutations can contribute to the development of lung cancer. Two proteins can become involved in cancerous mutations, Epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (Alk). Dr Jouida aims to determine the frequency of EGFR and Alk mutations in an Irish population, and correlate this with clinical outcome, cancer stage and smoking status. This translational medicine project aims to use exosome biology to identify potential biomarkers to allow the potential development of targeted therapies defined by the patient’s tumour profile. The ultimate aim is to improve patient care. Dr Jouida is mentored by Professor Michael Keane and based at the UCD Conway Institute of Bimolecular and Biomedical Research.
Primary progressive multiple sclerosis is a chronic neurological condition resulting in progressive problems with mobility, bladder control etc. Up until recently there were no treatments available to slow this progression. Until now. A new infused therapy is now licensed, Ocrelizumab. In addition to monitoring how people respond to this treatment with MRI scans and clinical examinations Dr Gaughan’s Fellowship will investigate the benefit of monitoring the levels of certain proteins (neurofilaments) in blood and spinal fluid (CSF) which may give a better idea of who is responding to the treatment. Little is known about the se neurofilaments in progressive MS and therefore we aim to analyse their levels in people with primary progressive MS who are not on any treatment and then see if the change after treatment is started. Dr Gaughan is mentored by Prof Chris McGuigan and is based in the UCD School of .
Dr Christine Shan has been awarded the Kerry Group Newman Fellowship in Food Safety. In recent years, EU-China trade relations have grown very fast and agriculture has become an important sector for EU imports from, and exports to, China. However, many trade barriers relating to safety issues, standardisation and traceability (including fraud) in agri-food products persist and hamper trade predictability. Dr Shan’s research will seek to address food safety standards, food authentication and consumer confidence issues with a view to facilitate mutual trade in agri-food inputs, human food ingredients and finished products. Mutual recognition of policies and controls can only be achieved if they are based on the same scientific approaches. By having regulators, scientists and industry in both jurisdictions working closer together, it is hoped that end to end supply chain security will be strengthened and consumer confidence will be enhanced. Dr Shan will be mentored by Professor Pat Wall and will be based in the School of Public Health, Physiotherapy and Sports Science.
Dr Daniel Hurley received his PhD in Computational Infection Biology from UCD in 2018. Since then, he has been working as a bioinformatician/molecular microbiologist in the UCD Centre for Food Safety. There he was working on strategies to characterise the bacterial communities of production environments.
Dr Hurley’s Fellowship intends to extend and deepen the ongoing collaboration that exists between the UCD-Centre for Food Safety and the Food Safety Authority of Ireland. His research will seek to explore the application of bespoke bioinformatics workflows, developed at UCD-CFS, for risk assessment in the context of the National regulator. Based on the determination of bacterial genome sequences from isolates of importance to human health, genetic markers will be identified and assessed for their potential to contribute to foodborne human infections. These will include, but are not limited to, genes encoding resistance to antimicrobial compounds including biocides as well as known virulence factors. From a public health perspective, this project constitutes a unique opportunity to contribute to the control of the emergence of foodborne pathogens from diverse sources including clinical, environmental, foodborne and veterinary.
Dr Ciara Egan received her Bachelor of Medicine, Bachelor of Surgery from the Royal College of Physicians Ireland in 2011. She went on to take up the position of SHO (Senior House Officer) at the Midlands Regional Hospital, Tullamore and St James’s Hospital, Dublin. Most recently, she was Specialist Registrar at St Vincent’s University Hospital, Dublin. Dr Egan began training in endoscopy in July 2015. To date, she has completed 600 gastroscopies and 400 colonoscopies. She has experience in PEG, tube insertion, polypectomy, band ligation for oesophageal varices and GAVE and stricture dilatation.
Dr Egan’s Newman Fellowship will see her trial the ability of testing for markers of blood or inflammation in the stool to select patients most likely to require further investigation and a camera test. She will aim to collect a blood sample from those considered at higher risk based on their stool test to explore if there are markers in their blood that may help in the diagnosis of bowel diseases.
IBD has no cure. The treatment relies on reducing symptoms, mainly with anti-inflammatory drugs and corticosteroids. One important treatment is the injection of anti-TNF antibodies, however, 40% of patients with IBD failure anti-TNF treatment. During her Abbvie Newman Fellowship, Dr Vanessa Bittencourt will characterize molecular mechanisms that are associated with this therapy resistance. She will recruit IBD patients receiving anti-TNF and monitor their clinical response and will work with peripheral blood and tissue samples from patients. This research will focus on IL-12p40 and IL-23 signaling pathways and the role of monocytes (main producers of these cytokines) in the pathogenesis of IBD.
Vanessa did her undergrad in Pharmacy at Brazil (UEPG), master’s degree in Biotechnology at Taiwan (NCKU) and completed a PhD in Biochemistry and Immunology at Ireland (TCD). She has a strong background in immunometabolism and immunology and has a great interest in studying IBD. Some of her own family have been diagnosed with IBD so Vanessa knows how life can be particularly challenging for people with this disease.
Vanessa is being mentored by Professor Glen Doherty and is based at the Centre for Colorectal Disease, St Vincent’s University Hospital.
Dr Julie Morrissy is an Irish poet, academic, critic, and activist. She is a recipient of the Next Generation Artist Award from the Arts Council. Her first collection ‘Where, the Mile End’ is published by Book*hug (Canada) and tall-lighthouse (UK & Ireland). Her debut poetry pamphlet I Am Where (Eyewear, 2015) was shortlisted for Best Poetry Pamphlet in the Saboteur Awards 2016.
Julie holds a PhD in Creative Writing from Ulster University, and degrees in Literature, and Law. Her creative and critical work has been published in Ireland, Canada, the U.S., and the UK, and she has represented Ireland at O, Miami Festival, and the Toronto International Festival of Authors. Morrissy lives and works in Dublin.
Kieran graduated from UCD School of Medicine in 2010. He worked as a specialist registrar in the Centre for Arthritis and Rheumatic Diseases and previously worked in the Mater Misericordiae University Hospital, Royal Perth Hospital, Beaumont Hospital and University College Hospital Galway. His main research interest is improving outcomes in inflammatory arthritis, through analysing biomarkers, infection risk and management in pregnancy. Kieran will use his Newman Fellowship to assist in the identification of new disease markers, drug targets, and drug candidates for the treatment of patients at different stages of rheumatoid arthritis progression and possibly other autoimmune diseases. He is mentored by Professor Doug Veale and based in the UCD School of Medicine and the Education and Research Centre in St Vincent’s University Hospital.